Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19 Post author: Post published: October 24, 2023 Post category:uncategorized Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. You Might Also Like Real-time smartphone monitoring improves evaluation of insomnia treatment effectiveness January 8, 2026 New stem cell model mimics alpha cell behavior in diabetic conditions May 8, 2025 Artificial ligaments could revolutionize ACL surgery and recovery February 27, 2025
Real-time smartphone monitoring improves evaluation of insomnia treatment effectiveness January 8, 2026